Extendicare Inc.
TSX:EXE.TOMedical - Care Facilities
+$0.86 today
- Market cap
- $2.74B
- Beta
- 1.16
- P/E (TTM)
- 26.4
- EPS (TTM)
- $1.28
- Dividend yield
- 1.51%
Volume 0.86M
Average 0.34M
Returns on capital
Extendicare Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
25.9%
avg 41.3%
ROIC
13.6%
avg 7.8%
ROA
9.1%
avg 6.7%
Analysis
ROE is currently the strongest return metric at 25.9% versus its period average of 41.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael R. Guerriere | Chief Executive Officer, President & Director | CAD 1.6M | 61 | — | — |
David E. Bacon | Executive Vice President & Chief Financial Officer | CAD 861.49K | — | — | — |
John Toffoletto | Senior Vice President, Chief Legal Officer & Corporate Secretary | CAD 800.24K | — | — | — |
Steve Paraskevopoulos | Senior Vice President of ParaMed & Chief Technology Officer | CAD 695.43K | — | — | — |
Matthew Morgan | Chief Medical Officer | CAD 574.7K | — | — | — |
Katie LeMoyne | Senior Vice President & Chief Human Resources Officer | CAD 520.06K | — | — | — |
Jillian E. Fountain | Vice President of Investor Relations | CAD 291.52K | — | — | — |
Joe Belinsky | Vice President of Information Technology & Chief Information Officer | — | — | — | — |
Kathryn Bradley | Senior Vice President of Corporate Development | — | — | — | — |
Danielle Labossiere Parr | Vice President of Public Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +9.3% | +16.5% (3yr)3 analysts |
| Revenue | N/A | N/A | +10.8% | +17.4% (3yr)5 analysts |
| Net Income | N/A | N/A | +11.6% | +16.4% (3yr)5 analysts |
| EBIT | N/A | N/A | +87.5% | +24.7% (3yr)5 analysts |
Analysis
Recent growth has been strongest in EBIT at +87.5% over three years. Forward estimates point to EBIT at +24.7% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Extendicare Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EXE.TO's management, answered from reported figures.
Who manages EXE.TO?
Extendicare Inc. (EXE.TO) lists 10 active executives. The top listed executive is Matthew Morgan, Chief Medical Officer.
Continue the stock analysis
Jump to another research area for this company.